Higher Susceptibility of Erythropoietin-Producing Renal Cell Carcinomas to Lysis by Lymphokine-Activated Killer Cells

Journal of Immunotherapy

Volumn 19, Issue 6, 1996, Pages 399-404

  Miyajima, Jiro ^a   Imai, Yasuhisa ^a   Nakao, Masanobu ^a   Noda, Shinshi ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Erythropoietin; Immunotherapy; Laboratory marker; LAK cells; Renal cell carcinoma

Indexed keywords

ERYTHROPOIETIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CYTOLYSIS; ERYTHROPOIESIS; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; PRIORITY JOURNAL;

CARCINOMA, RENAL CELL; CYTOTOXICITY, IMMUNOLOGIC; DNA, COMPLEMENTARY; ERYTHROPOIETIN; HUMANS; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0030326694     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199611000-00003     Document Type: Article

References (15)

1. Budd GT, Murthy S, Finke J. Phase I trial of high dose bolus IL-2 and IFN2a in patients with metastatic malignancy. J Clin Oncol 1992;10:804-9.
2. Figlin RA, Belldegrun A, Moldawer N, Zeffren J, Dekernion J. Con-comitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 1992;10:414-21.
3. Schwartzentruber DJ, White DE, Zweig MH, Weintraub BD, Rosenberg SA. Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 1991;68:2384-90.
4. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85:622-32.
5. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. J Exp Med 1988;168:1419-41.
6. Hayakawa K, Morita T, Augustus LB, von Eschenbach AC, Itoh K. Human renal cell carcinoma cells are able to activate natural killer cells. Int J Cancer 1992;51:290-5.
7. Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Research 1988;48:206-14.
8. Alexander J, Rayman P, Edinger M, et al. TIL from renal cell carcinoma: Restimulation with tumor influences proliferation and cytolytic activity. Int J Cancer 1990;45:119-24.
9. Hayakawa K, Salmeron MA, Parkinson DR, et al. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J Immunother 1991;10:313-25.
10. Janik JE, Sznol M, Urba WJ, et al. Erythropoietin production: A potential marker for interleukin-2/interferon-responsive tumors. Cancer 1993;72:2656-9.
11. Hirohisa Y, Maruiwa M, Sugihara S, Kojiro M, Noda S, Eto K. Establishment and characterization of new human renal cell carcinoma cell lines (KRC/Y). In Vitro Cell Dev Biol 1988;24:9-16.
12. Shichijo S, Hayashi A, Takamori S, et al. Detection of MAGE-4 protein in lung cancers. Int J Cancer 1995;64:1-8.
13. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313:806-9.
14. Nakao M, Yamana H, Imai Y, Toh Y, Toh U, Kimura A, Yanoma S. et al. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Research 1995;55: 4248-52.
15. + lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL-2)-induced activated killer (AK) cells. J Immunol 1985;134:802-7.